Project: Development of a novel AhR-based Cancer Treatment

ACT aims to establish preclinical efficacy and safety for a novel drug targeting advanced triple negative breast cancer (TNBC) via modulation of the aryl hydrocarbon receptor (AhR). The AhR is activated by aromatic hydrocarbons present in pollutants and is highly expressed in TNBC and other tumours. AhR activation has been linked to tumour initiation and metastasis, which can be significantly inhibited by AhR modulators. Our candidate compounds thus represent highly promising anti-cancer drugs.

Acronym	ACT (Reference Number: 9671)
Duration	01/10/2015 - 01/10/2018
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 3

Project partner

Number	Name	Role	Country
21268	Hercules Pharmaceuticals B.V.	Coordinator	Netherlands
21269	Quay Pharmaceuticals Ltd.	Partner	United Kingdom
21270	Pharmatest Services Ltd.	Partner	Finland
21271	Pipeline Biotech A/S	Partner	Denmark
21272	Cellvax SAS	Partner	France